Guide: Essential Principles & Practices for GPP Compliance: Engaging stakeholders in biomedical research during the era of COVID-19by Mesh Editorial Team
This tool from AVAC in intended to help guide stakeholder engagement in COVID-19 research. Built from the Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP), it responds to needs expressed by both researchers and advocates.
This toolbox was developed in 2020 for the World Health Organisation COVID-19 Research Roadmap and provides a synthesis of key action points from the WHO GPP-EP guidelines. This “how to” guide gives an overview, tips and resources and will be updated as new resources are completed and approved.
GPP-EP were prepared in 2016 by the WHO to support prevention and treatment trials of emerging (and re-emerging) pathogens that were likely to cause severe outbreaks. The guidelines address how to engage community stakeholders and promote ethical standards throughout the research process.
Although these Good Participatory Practice (GPP) Guidelines were developed by AVAC and UNAIDS for HIV prevention trials, they are valuable to clinical trials across fields, research areas, geographies and populations.
Providing guiding principles and practice standards for stakeholder engagement as an integral part of TB drug trials. Stakeholder engagement refers to any form of consultation, collaboration, and partnership put in place to enable a dialogue between all parties having a stake in a specific trial.